

Table 1. Detection of antiviral drug-resistant viruses in Japan during the 2022/2023 influenza season

as of February 20, 2024

	A(H1N1)pdm09						A(H3N2)						B				
	Baloxavir	Oseltamivir	Peramivir	Zanamivir	Laninamivir	Amantadine	Baloxavir	Oseltamivir	Peramivir	Zanamivir	Laninamivir	Amantadine	Baloxavir	Oseltamivir	Peramivir	Zanamivir	Laninamivir
Resistant (%)	1 (1.4%)	1 (0.9%)	1 (0.9%)	0	0	72 (100%)	11 (1.8%)	0	0	0	0	337 (100%)	0	0	0	0	0
Number of viruses tested	70	112	112	69	69	72	607	330	330	330	330	337	51	49	49	49	49
Number of viruses reported	202						3,558						86				

Baloxavir was examined by focus reduction assay, rhPCR allelic discrimination and/or PA sequencing.

NA inhibitors were examined by fluorescence-based NA-Fluor assay, chemiluminescence-based NA-XTD assay, real time RT-PCR allelic discrimination and/or NA sequencing.

Amantadine was examined by M2 sequencing.